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Abstract: Squalene (SQ) is a natural triterpene widely distributed in nature. It is a metabolic
intermediate of the sterol biosynthetic pathway and represents a possible target in different metabolic
and oxidative stress-related disorders. Growing interest has been focused on SQ’s antioxidant
properties, derived from its chemical structure. Strong evidence provided by ex vivo models
underline its scavenging activity towards free radicals, whereas only a few studies have highlighted
its effect in cellular models of oxidative stress. Given the role of unbalanced free radicals in both the
onset and progression of several cardiovascular diseases, an in depth evaluation of SQ’s contribution
to antioxidant defense mechanisms could represent a strategic approach in dealing with these
pathological conditions. At present experimental results overall show a double-edged sword role of
squalene in cardiovascular diseases and its function has to be better elucidated in order to establish
intervention lines focused on its features. This review aims to summarize current knowledge
about endogenous and exogenous sources of SQ and to point out the controversial role of SQ in
cardiovascular physiology.
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1. Introduction
Squalene (SQ) is a lipophilic biomolecule that belongs to the chemical class of triterpenes. It is
formed by six isoprene units, so, it is a 30-carbon isoprenoid compound with six double bonds (C30H50).
SQ is an odorless, colorless, liquid oil. The molecule was named squalene because it was initially
isolated by Tsujimoto from shark (Squalus milsukurii and other squaloids) liver oil [1–3], but subsequent
studies have also found this compound in several plant extracts [4].
In eukaryotic cells SQ is a metabolic intermediate in the sterol biosynthetic pathway [5]; squalene
synthase, an enzyme associated with the membrane of the endoplasmic reticulum, catalyzes the
biosynthesis of SQ in a two-step reaction starting from two units of farnesyl diphosphate [6]. SQ is the
precursor of cholesterol in animal cells and the precursor of phytosterols in plant cells (Figure 1).
As an intermediate in sterol biosynthesis, SQ plays a crucial role in plant and animal organisms [1,7].
Several in vitro and in vivo studies have already underlined the antioxidant effects of SQ, probably
due to its molecular properties directly linked to its activity towards free radicals [1,2,8]. In fact, due to
its conformation, it can easily move through cellular and subcellular membranes, allowing rapid
distribution in every cell compartment [9]. In addition, it acts as scavenger and quencher against some
free radicals. In particular, SQ breaks lipid peroxidation chains both in the initial phase and in the
propagation phase [8].
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Figure 1. Biosynthetic pathway of animal and plant sterols. Squalene is synthesized from two units 
of farnesyl diphosphate by squalene synthase and then converted in 2,3-epoxysqualene, the 
precursor of animal and plant sterols. The animal sterols cholesterol and ergosterol originate from 
lanosterol, while the plant sterols, stigmasterol, β-sitosterol, campesterol and fucosterol, originate 
from cycloartenol. 
However, SQ’s role in the prevention or treatment of oxidative stress-related cardiovascular 
diseases (CVDs) is still controversial and further studies are needed to investigate the correlation 
between high plasma SQ concentrations and CVDs.  
This work focuses on current knowledge about SQ roles in humans, its endogenous and 
exogenous sources, and its beneficial and negative impact on health, with particular attention to 
metabolic and cardiovascular disorders. 
2. Sources of Squalene 
2.1. Endogenous Sources of Squalene 
In human body, squalene is present in multiple organs and tissues. As expected, the liver is the 
main player of its biosynthesis and this organ represents the primary way through which SQ enters 
the systemic circulation. Animal studies demonstrate that interference in cholesterol biosynthesis in 
liver could influence squalene concentration both at the local (in hepatocytes) and systemic levels 
[10].  
SQ is present in plasma embedded into lipoproteins: its concentration is particularly high in 
very low density lipoproteins (VLDL), but significant concentrations of SQ are also found in low 
Figure 1. Biosynthetic pathway of animal and plant sterols. Squalene is synthesized from two
units of farnesyl diphosphate by squalene synth se and then converted i 2,3-epoxysqualene, the
precu sor of animal and plant terols. The animal sterols cholesterol and ergoster l originate from
lanoster l, while the plant sterols, stigmasterol, β- itosterol, campesterol and fucoste ol, originate
from cycloartenol.
However, SQ’s role in the prevention or treatment of oxidative stress-related cardiovascular
diseases (CVDs) is still co troversial and further studies are needed to investigate the correlation
between high plasma SQ concentrations and CVDs.
This work focuses on urrent knowledge about SQ roles in humans, its endogenous and exogenous
sources, and its beneficial and negative impact on health, with particular attention to metab lic
cardiovascular disorders.
2. Sources of Squalene
2.1. Endogenous Sources of Squalene
I human body, squalene is present in multiple organs and tissues. As expected, the liver is the
main player of its biosynthesis and this organ represents the primary way through which SQ enters the
systemic circulation. Animal studies demonstrate that interference in cholesterol biosynthesis in liver
could influence squalene concentration both at the local (in hepatocytes) and systemic levels [10].
SQ is present in plasma embedded into lipoproteins: its concentration is particularly high in very
low density lipoproteins (VLDL), but significant concentrations of SQ are also found in low density
Antioxidants 2020, 9, 688 3 of 14
lipoproteins (LDL) and high density lipoproteins (HDL), and its amount seems to be directly correlated
with triglyceride abundance in these components [11,12].
Because of SQ hydrophobic nature, it could be found in a concentration of 275 µg/g in
adipocytes [13]. Squalene constitutes about 12% of the human skin surface lipids [14], probably
because, compared with other mammals, human skin is not so hairy, and therefore it needs more
strategies to counteract the photo-oxidative action of UV rays [15]. Moreover, several research studies
have pointed out SQ high concentrations (about 475 µg/g) in epithelial tissue, suggesting a possible in
loco synthesis of this compound, where sebaceous glands figure as probable sources of SQ [4,11,13].
2.2. Exogenous Sources of Squalene
Recent studies have highlighted exogenous natural or synthetic sources of squalene. Indeed,
SQ can be introduced through food products, food supplements and drugs [2]. As previously
mentioned, SQ was first isolated from shark liver oil in which its concentration reaches nearly 40%
of the total oil [2,11,13]. A shark’s liver can constitute up to 25% of its body mass, and the role of
squalene in the liver is known to contribute together with diacyl glycerol esters to the control of animal
flotation [16]. Several works point out and support its dermatological use [15]. Fortunately, today
cosmetic industry is strictly regulated by laws which protect these animal species and SQ has to be
isolated from other natural or synthetic sources.
In this scenario plants, where it is a precursor of phytosterols and other secondary plant metabolites,
figure as alternative natural sources of squalene. SQ is highly concentrated in the unsaponifiable part
of several plant oils. Furthermore, several studies demonstrate that plant levels of squalene are strictly
correlated to the plant source, the location and period of plant growth and the extraction method used
to separate SQ from other metabolites [11]. Considering all these factors, it could be necessary to use
high quantities of raw materials to extract SQ from plant rather than animal sources. For these reasons
several methods have been applied in order to reach higher concentrations of SQ in plant extracts.
In addition to traditional mechanical and chemical extraction, using ethanol [17], new approaches have
been developed with successful results, such as supercritical CO2 extraction [17–19].
The most relevant plant sources of SQ are oils extracted from amaranth, olive, rice, wheat germ,
grape seed, peanut and soybean [4,11,20]. As previously mentioned the abundance of SQ in the
extract is influenced by several factors, but promising results obtained in this research field offer
positive data on the possible use of plant-derived SQ in pharmaceutical and cosmetic sectors and in
the nutraceutical field.
Regarding exogenous SQ fate in the digestive tract, animal and human studies have already
tested the bioavailability of dietary SQ, underlining that nearly 60% of the ingested compound is
absorbed. Non-absorbed SQ is in part excreted with feces and the rest probably metabolized by the
gut microbiota, however further studies are needed to elucidate this pathway [21,22].
3. ROS/RNS and Squalene
3.1. ROS/RNS and Squalene
Oxidative stress leading to lipid peroxidation is triggered by different oxidizing molecules and,
among them, O2• is the first reactive oxygen species (ROS) involved in the damage of cell membranes.
The presence of SQ seems to reduce this radical by releasing an electron, through reaction (1), at the
moment observed only in ex vivo models and not yet demonstrated in cellular systems:
SQ + O2•→ HOO-SQ (1)
The stabilization of the radical occurs through the formation of a squalene hydroperoxide
(HOO-SQ) and the electronic rearrangement of SQ by resonance, a typical phenomenon related
to molecules containing a number of double bonds [23]. This reaction leads to the formation of
different isomers, which are specifically: 2-OOH-SQ, 3-OOH-SQ, 6-OOH-SQ, 7-OOH-SQ, 10-OOH-SQ,
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11-OOH-SQ. In particular, the study by Shimizu et al. [14], examined this behavior by oxidizing SQ
with 3-(1,4-epidioxy-4-methyl-1,4-dihydro-1-naphytyl)propionic acid (EP), a compound used to release
O2 by thermal degradation. SQ oxidation occurs in a dose dependent fashion and the different isomers
are produced in the same percentages. During this reaction O2• acts as an oxidizing agent and reacts
with a double bond to form hydroperoxides through the ene-reaction [24].
The rate of this reaction is expressed through a kinetic constant: the quenching constant (Kq).
Krasnovsky and colleagues calculated this value as the sum of three other kinetic constants [25]: Kph:
expresses physical quenching; K1: expresses kinetics reaction occurring between an oxidizing agent
and an allylic hydrogen atom of the reducing agent, which is part of a methylene group between C=C
and C–C; K2: expresses kinetics reaction occurring between an oxidizing agent and an allylic hydrogen
atom of the reducing agent, which is part of a methylene group between C=C and C=C. Since SQ does
not have conjugated double bonds, this value is equal to 0.
Squalene Kq (KqSQ) has been measured by Kohno et al. [8], in an environment saturated with
butanol at 35 ◦C. KqSQ (2.66 × 106 M−1 s−1) is greater than the Kq of some membrane lipids, such as
ethyl linolenate, eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester. Since the Kq of
saturated and monounsaturated fatty acids is lower than that of polyunsaturated acids [25], and KqSQ
shows the highest value among membrane polyunsaturated acids, the stabilization reaction will take
place faster in presence of SQ rather than other membrane lipids. Therefore, SQ oxidation occurs earlier
than other lipids, blocking the peroxidative reactions and thus protecting cell membranes. Furthermore,
KqSQ has a lower value than Kq of α-Tocopherol, but similar to the Kq of dibutylhydroxytoluene (BHT)
molecules, widely used as antioxidants in food industry.
Moreover, SQ is inserted in cell membrane and contributes to its stabilization [26,27]. In particular,
in the plasma membrane, due to its hydrophobicity, it is oriented parallel to the plane of symmetry of
the lipid bilayer, embedded between fatty acids terminal methyl groups of the two layers. The strategic
position of SQ forms an intermediate barrier between the two phospholipidic layers and allows the
molecule to act as a quencher that blocks uncontrolled electron flows. The role of SQ in stabilizing
cell membranes underlines its important role also in cardiac cell membrane reconstitution and in the
regulation of membrane proteins and ion movement [26].
3.2. Oxidative Stress in Skin and Squalene
Antioxidant properties of SQ were primarily studied in epithelial tissue. In fact, the molecule
is highly abundant in skin, that is the largest tissue exposed to different environmental stressors
leading to oxidative stress, such as pollutants, photo-oxidation and UV-light. In particular, Aioi and
colleagues show the scavenging activity of SQ on superoxide anion formation in keratinocytes exposed
to oxidative stressors [28], suggesting a protective role of the molecule that acts in combination to
superoxide dismutase.
3.3. Cardiovascular Antioxidant Systems and Squalene
Recent studies, aiming to evaluate the effect of SQ on antioxidant enzyme levels and activity in
cardiovascular and hepatic tissues, showed a positive correlation between SQ and glutathione and
non-glutathione-dependent enzymatic defenses. In fact, even if the first antioxidant activity of SQ
is linked to lipid peroxidation blockade, as already described, growing evidence is emerging on its
involvement in the regulation of the expression and activation of glutathione peroxidase (GPx), catalase
(CAT), superoxide dismutase (SOD) and glutathione S-transferase (GST) [29,30]. SQ prevents the
alterations of SOD and CAT by detoxifying the cytosolic environment. Moreover, it acts reconstituting
GSH and safeguarding the enzymatic activity of GPx. Furthermore, the GSSG/GSH ratio, which is
considered as a marker of oxidative stress status, decreases after SQ treatment [30].
The positive influence of SQ on antioxidant enzymes has been demonstrated in stress situations,
in particular, in animal models of isoproterenol-induced myocardial infarction [29]. Summarizing
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these results, it could be reasonable thinking the possible use of SQ in maintaining antioxidant enzyme
activity in the heart and vascular system.
Table 1 summarizes different works in which the antioxidant properties of SQ were evaluated in
cardiovascular system and in liver.
Table 1. Principal studies showing antioxidant effect of squalene in skin, liver and cardiovascular system.
Study Model Results
Aioi A. et al., 1995 [28]
Keratinocytes from shaved dorsal skin of
rats, measurements of O2− by reduction of
equine ferricytochrome c after treatment
with SQ and stressing agent
Inhibition of O2− production by
addiction of 100 mg/mL SQ
Buddhan S. et al., 2006 [31]
Young and old male Wistar albino rats fed
with a 2% SQ supplemented diet for 15 or
30 days
Inhibition of liver mitochondrial
lipid peroxidation, increased
levels of reduced glutathione and




Motawi T. M. K. et al., 2010 [32]
Male Wistar albino rats were administered
for 7 days with SQ (0.4 mL/rat) before and
after CP treatment
Improvement of GPx activity and
GSH levels in cardiac tissue
Gabás-Rivera C. et al., 2014 [33]
Wild-type, Apoa1- and Apoe- deficient
C57BL/6J male mice fed with 1 g/kg SQ for
11 weeks
Decreased ROS in lipoproteins
Ravi Kumar S. et al., 2016 [30]
Male KK-Ay mice fed high fat/sucrose diets
supplemented with 2% SQ in combination
with astaxanthin for 4 weeks
Elevated mRNA expression of
SOD1 and GPx1 in liver
4. Oxidative Stress Associated CVDs and Squalene
The endothelium lining the lumen of blood vessels is pivotal in maintaining vascular function
and its regulation has an important redox component. In fact, physiological ROS levels contribute
to vasodilatation, angiogenesis, vascular remodeling and maintenance of lower blood pressure [34].
The main source of ROS in the vasculature is the NADPH oxidase (NOX). NOX-derived ROS act
as essential second messenger molecules contributing to the regulation of normal cell function [35].
NOX4 and NOX2 isoforms are the major ROS producers in vascular smooth muscle cells and
endothelial cells. In particular, H2O2 produced by NOX4 activates eNOS leading to the generation
of NO, which exerts vasoprotective effects on the endothelium keeping blood vessels dilated and
controlling blood pressure [36,37]. Moreover, vascular endothelial growth factor (VEGF), a physiological
regulator of angiogenesis, induces endothelial ROS production through NOX4 and NOX2 activation
and promotes endothelial cell proliferation, migration and survival [38]. In addition, normal levels
of ROS are critical for the physiological response of vascular smooth muscle cells. In particular
NOX4-induced H2O2 promotes cell differentiation and the phenotypic switch from a proliferative state
to a contractile state, regulating the vascular tone [39].
Moreover, NOX4 is expressed not only in endothelial and vascular smooth muscle cells, but also
in cardiomyocytes, in which it regulates autophagy, leading to its steady activation, and cytoprotective
and antioxidant pathways [40].
Adverse cardiocirculatory events induced by oxidative stress are primarily linked to endothelial
dysfunction [41–44], characterized by a complex multifactorial pathway, including eNOS uncoupling
and increased concentration of inflammatory cytokines, both exacerbating the damaging effect induced
by ROS/RNS boost [41]. Among risk factors that contribute to the development of endothelial
dysfunction, some are classified as non-modifiable factors, as aging and family history of CVDs,
other are classified as modifiable risk factors and are related to lifestyle [41].
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The following paragraphs describe the role of SQ in different oxidative stress associated CVDs,
that are strictly linked to endothelial dysfunction development, and underline the possible use of SQ
as a natural supplement to support standard drug therapy.
4.1. Hypercholesterolemia
Hypercholesterolemia is a metabolic disorder characterized by high levels of circulating low
density lipoproteins (LDL) and related adverse effects. According to clinical health guidelines, reference
values are: total cholesterol < 200 mg/dL, LDL < 100 mg/dL and HDL > 50 mg/dL; higher circulating
values of total cholesterol and LDL have to be considered as hypercholesterolemic conditions [45].
Presence of high levels of LDL and ROS can contribute to the development of atherosclerosis:
oxidized LDL (oxLDL) are taken up by macrophages that become foam cells; macrophages also
produce cytokines that recruit T cells that are involved in amplifying the inflammation. Endothelial
cells produce cytokines that stimulate smooth muscle cell proliferation and migration; foam cells and
smooth muscle cells form a lipid core surrounded by fibrotic tissue, the atherosclerotic plaque, highly
susceptible to rupture and thrombus formation [42]. Given the high instability of the plaque and the
possible negative effects derived from its rupture, it is important to interfere with both its onset and
progression with hypocholesterolemic agents.
SQ, as a precursor of cholesterol, could be reasonably considered as an exacerbating factor
for hypercholesterolemia. Despite that, Khor et al. demonstrated that addition of SQ to a high
fat diet in hamsters does not affect levels of LDL, HDL and triglycerides and that the increased
cholesterol ester accumulation in SQ fed hamster liver could account for the hypocholesterolemic
effects of the supplemented chow [46,47]. Furthermore, Kritchevsky and colleagues demonstrated
that a SQ based diet for 7 weeks in rabbits does not induce atheroma formation neither is directly
involved in atherosclerosis development [46,48]. Other studies underline sex-related responses to SQ
supplementation in ApolipoproteinE (ApoE-/-) KO mice, a useful animal model for atherosclerosis:
males show a reduction of atherosclerotic lesion area independently from plasmatic lipid panel,
while females do not show a reduction of atherosclerotic lesion area, but have significantly reduced
plasma levels of cholesterol and triglycerides [49]. Other studies pointed out the molecular mechanism
involved in SQ effects, some of them highlighting the activation of liver X receptors (LXRs), nuclear
receptors engaged in homeostasis of cholesterol, fatty acids and glucose. In particular, a recent
study shows that SQ acts as a selective modulator of LXRs in macrophages, inhibiting cholesterol
accumulation and promoting its efflux; moreover, in hepatocytes SQ activates PPARα, thus upregulating
the expression of genes related to fatty acid uptake, fatty acid oxidation, ketogenesis and reverse
cholesterol transport metabolism. Based on these considerations, SQ represents a natural compound
that can be used in dyslipidemic patients without negative side effects induced by standard administered
drugs [50,51].
Granados-Principal and colleagues also studied SQ role in atherosclerotic plaque formation:
they observed a dose-dependent reduction of surface expression of the oxLDL receptor CD36,
in monocytes and macrophages and a consequent reduction in oxLDL uptake; furthermore, SQ exerted
antiproliferative effect on monocytes and macrophages, thus contributing in atherosclerosis decline [52].
SQ also seems to be directly involved in cholesterol synthesis break, through a negative feedback
mechanism: SQ alone or in combination with hypocholesterolemic drugs, such as statins, promotes
both the down-regulation of HMG-CoA reductase, a key enzyme in cholesterol biosynthesis, and the
cholesterol and bile acid excretion [53,54].
4.2. Hypertension
Hypertension is a complex, multifactorial, and multisystem disorder. Several studies have shown
that endothelial dysfunction is an early and common trigger of hypertension and it is characterized by
an impairment of the physiological pathways controlling vascular tone, primarily the NO pathway.
Burst of ROS in dysfunctional endothelial cells lead to the irreversible production of peroxynitrite
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(ONOO−); ONOO− can rapidly diffuse trough the cell and oxidize proteins, inducing eNOS uncoupling
and thus decreasing NO production [55]. Furthermore, high ROS levels enhance angiotensin II
signaling in resistance arteries and induce vascular smooth muscle cell hypertrophy [38].
New antihypertensive approaches based on nutraceutical properties of some food and plant
extracts and, among them, squalene has shown positive effects in lowering blood pressure. Martirosyan
and colleagues reported that SQ-rich amaranth oil reduces systolic blood pressure in a concentration
dependent way [56]. Furthermore, Liu et al. showed that orally administered SQ for 4 weeks in rats
diminishes both plasma lipids and blood pressure, probably through a reduction in circulating levels
of leptin [46,57].
4.3. Hyperglycemia-Dependent Endothelial Dysfunction
Hyperglycemia is characterized by high fasting glucose levels in plasma, >200 mg/dL, due to
genetic factors or wrong lifestyle habits. Chronic high glycemia causes enhancement of different
molecules, in particular, polyol, advanced glycation end products, protein kinase C and exosamine,
all involved in multiorgan damages. ROS rising, due to NOX enhanced activity and eNOS uncoupling,
is strictly related to endothelial dysfunction associated to hyperglycemia [58]. Whereby dietary
interventions in reducing glycemia are scant, hypoglycemic drugs are prescribed.
In recent years, many studies have suggested the use of plant extracts in order to lower plasma
glucose and to prevent the development of ROS-induced endothelial dysfunction: among them,
squalene is proposed as an antioxidant molecule capable of lowering both endothelial ROS and
glycemia in hyperglycemic patients. At this regard, Liu and colleagues observed a reduction in plasma
glucose in male Wistar rats fed with a high SQ diet in a time-dependent trend [57], while, Widyawati
and collaborators highlight an hypoglycemic effect of a SQ-rich extract of Sygyzium polyanthum,
mediated by a reduced glucose absorption in the gut and by an increased glucose uptake in the
skeletal muscle [59]. Conversely, Valdes et al. showed no significant blood glucose reduction by SQ
in streptozotocin-induced diabetic mice, pointing out the need of further investigation to define the
hypoglycemic role of SQ [60].
5. Pathological Implications of Squalene
As a precursor of cholesterol biosynthesis, SQ both from endogenous or exogenous sources [61,62],
the roles of SQ as a marker or a risk factor in the development of CVDs are essential. In order to
define SQ implication in cardiovascular pathology, a few studies underline the possible strategic role
of the molecule in coronary artery disease (CAD) [63] and in the development of visceral obesity and
metabolic syndrome [64,65]. Moreover, emerging therapies for dyslipidemia are addressed to squalene
synthase as a possible pharmacological target [21,66,67].
5.1. Coronary Artery Disease
Coronary artery disease (CAD) is a pathological condition characterized by atherosclerotic
plaque formation in coronary vessels and it is strictly related to oxidative stress status. CAD is a
multifactorial pathology in which both genetic and environmental factors contribute to its development.
Studies underline different risk factors that are involved in the progression of this condition, among
others, high LDL and low HDL cholesterol in plasma, hypertension, diabetes, smoking, sex and age.
CAD could open to more severe conditions such as myocardial infarction and heart failure, so, it is
important to stop the progression of the pathology lowering existing risk factors [68]. Rajaratnam
and colleagues underline that in menopausal women high plasma concentration of squalene could
represent a risk factor for CAD: they found higher plasma SQ related to serum cholesterol in women
with cardiovascular predisposition to CAD than in controls. Moreover, elevated concentration of SQ
were found in atherosclerotic plaques delivered by LDL [63]. The authors ascribed the high serum
concentration of SQ to the decreased cholesterol synthesis resulting from hypercholesterolemic diet,
and suggest SQ as a marker for CAD diagnosis [63,69–71].
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5.2. Metabolic Syndrome
Metabolic syndrome is a multifactorial disease characterized by dyslipidemia, hypertension,
diabetes and obesity [72,73]. Several interventions are needed to reverse this condition: life style
changes are the first line modifications, and, to overcome critical situations, drug administration could
be necessary.
In this scenario, abdominal adiposity and obesity are evident phenotypes of metabolic syndrome,
when other latent symptoms are not yet manifested. Peltola and colleagues highlighted that high levels
of serum SQ are linked to visceral obesity; as adipose tissue synthesizes and stores SQ, which is only in
part converted to cholesterol, the authors suggest that SQ in adipose tissue could have detrimental
effects in abdominal obesity, thus suggesting SQ as marker for metabolic syndrome [65]. According to
these results, Lupattelli and collaborators demonstrated that in metabolic syndrome low synthesis
of cholesterol and high absorption of SQ occur, thus explaining its high plasma concentrations [64].
Only a few data are available defining the critical role of SQ in metabolic syndrome and in the control
of the resulting systemic oxidative stress status. They open essential questions about its direct or
simply marker role in the onset of the pathological picture typical of metabolic syndrome.
5.3. Squalene Synthase Inhibitors
In order to assess a complete description of current knowledge about squalene and CVDs. it could
be necessary also to define new advances in pharmacological therapies for dyslipidemia and the
role of SQ in this pathological condition, strictly associated with the rise of circulating free radicals.
Today most used drugs to treat dyslipidemia are statins, that block cholesterol biosynthesis inhibiting
HMG-CoA reductase activity, fibrates and bile-acid sequestrants [27,61,66]. New frontiers are under
investigation because these drugs have several adverse side effects when chronically administered.
For this reason, other enzymes in the cholesterol biosynthetic pathway are under investigation as
putative pharmacological targets; among them, squalene synthase (SQS) represents a good candidate
because it catalyzes one of the last reactions in cholesterol synthesis; indeed, its blockade does not
interfere with the synthesis of other fundamental intermediates in the pathway, such as geranylgeranyl
diphosphate or ubiquinone, and because only moderate side effect has been highlighted using this
approach [67].
As a consequence of inhibition of SQS, low levels of endogenous squalene are reached and this
may suggest a possible role of the molecule in the onset of hypercholesterolemia that have to be
confirmed with further investigations [61,62,66].
6. Nutraceutical Properties of SQ
Nutraceuticals are defined as foods or ingredients or natural extracts that have a role in promoting
health, thus preventing or treating some pathologies [74,75]. The previously described multiple
beneficial effects of SQ support its potential nutraceutical properties and its possible use as food
additive to prevent or treat some pathological conditions [74,75]. Toxicological studies show that SQ
is well tolerated when consumed orally and that it has faster time of absorbance when compared to
cholesterol [4,26].
Even if some nutraceutical properties of SQ have already been mentioned, recent animal studies
underline in a more detailed manner antioxidant and cardioprotective effects of SQ- enriched diets.
Indeed, SQ enriched diets show beneficial effects on mitochondrial energy status, lipid peroxidation
and membrane stability. A number of research groups observed a stronger scavenging activity of SQ
compared to vitamin E in elderly people [31]. Administration of SQ seems to have several positive
effects on cardiovascular system, reducing atherosclerosis through induction of paraoxonase 1 (PON1)
protective against the development of atherosclerosis [33], enhancing peripheral blood flow and
improving central arterial elasticity [76]. Moreover, chemoprotective effects of SQ are currently under
investigation [32,77–81].
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7. Squalene: Healthy or Harmful in CVDs? Summary and Future Directions
The aim of this paragraph is to summarize both positive and negative effects of SQ in CVDs, as emerged
from the previous sections, and to try to dissolve the vagueness around its pathophysiological role.
As pointed out in Table 2, all the results suggesting a role of SQ in the onset of CVDs arise
from correlation studies, while a number of research articles reporting positive role of SQ, properly
deepen the molecular mechanisms involved and this is in agreement with Ibrahim and colleagues [46].
Among them, activation of LXRs in macrophages [50], activation of PPARα in hepatocytes [51], reduction
of CD36 expression in monocytes and macrophages [52] and downregulation of HMG-CoA reductase
in the liver [53], strongly support the hypolipidemic role of SQ and its resulting anti-atherogenic
effect. Based on these observations, future studies in SQ and CVDs should focus on cellular and
molecular pathways directly affected by the triterpene, thus integrating clinical, cellular, molecular
and biochemical analysis.
Table 2. Correlation or molecular mechanism-based studies showing the effect of SQ in different pathologies.
Pathological Condition Reference Effects
Positive effects of SQ
Hypercholesterolemia
and atherosclerosis
Gabás-Rivera C. et al.,
2014 [33]
Induction of paraoxonase-1 and reduction
of ROS in lipoproteins in male mice fed
with a SQ enriched diet
Kritchevsky D. et al., 1954 [48]
Only correlation between
anti-atherosclerotic effect and SQ
enriched diet
Guillén N. et al., 2007 [49]
Only correlation between reduced plasma
cholesterol and triglycerides and SQ
enriched diet in female mice ApoE-KO
Hien H.T.M. et al., 2017 [50] Activation of LXR α and β in macrophages
Hoang T.M.H. et al., 2016 [51]
Activation of PPARα, induction of genes
involved in lipid metabolism with
hypolipidemic effect in HepG2 cells
Granados-Principal S. et al.,
2012 [52]
Reduced expression of CD36 in monocytes
and macrophages
Shin D.H. et al., 2004 [54]
Enhancement of cholesterol and biliary acid
excretion in rats fed SQ enriched diet;
inhibition of HMG-CoA reductase activity
after i.p. injection of SQ in rats
Hamadate N. et al., 2015 [76]
Enhancement of arterial elasticity in
middle-aged and elderly men fed with
shark liver enriched diet
Hypertension
Martirosyan, D.M. et al.,
2007 [56]
Reduction of systolic blood pressure after
SQ-rich amaranth oil supplemented diets
Liu Y. et al., 2009 [57]
Decrease of leptin levels and consequent
reduction of plasma lipids and
blood pressure
Hyperglycemia-induced
endothelial dysfunction Liu Y. et al., 2009 [57]
Lower glycemia in rats fed SQ
supplemented diet
Negative effects of SQ
Coronary Artery Disease Rajaratnam R.A. et al.,2000 [63]
Only correlation between elevated plasma
ratio of SQ to cholesterol and augmented
risk for coronary artery disease in
postmenopausal women
Metabolic syndrome Peltola P. et al., 2006 [65] Only correlation between high serum SQlevels and visceral obesity
8. Conclusions
Squalene is a key metabolite in the sterol pathway and it is pivotal in regulating cellular and
systemic physiology in eukaryotic organisms. Its role as a metabolic intermediate underlines its
involvement in the regulation of different biochemical pathways, such as the regulation of sterol
homeostasis (Figure 1). Despite the wide distribution of SQ in animal organisms, its direct role in
regulating both pathologic and non-pathologic conditions is an important frontier of investigation.
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In particular, its involvement in oxidative stress responses in human is still debated. Several
studies indicate a dual role of the compound primarily linked to its chemical structure: the possible
implication of SQ in antioxidant cellular response, and, in the other hand, the possible contribution of
SQ in exacerbating detrimental effects of oxidative stress associated diseases.
This review focuses on the role of SQ in the development of oxidative stress associated CVDs.
Treatment of most common CVDs, such as hypercholesterolemia, hypertension and hyperglycemia,
with SQ enriched-diet shows promising results, underlining both quenching activity and enhancement
of antioxidant systems induced by SQ against ROS/RNS burst [46]. Moreover, giving the emerging
pivotal role of LXRs as a beneficial modulator of cardiovascular physiology [82], and the recent findings
of SQ as an agonist of LXRs [50], future studies could be aimed at investigating the potential link
between squalene and LXRs in cardiomyocytes and endothelial cells and in deepen the resulting
intracellular pathway.
Even if chemical characterization and ex vivo results suggest a possible protective role of SQ
against oxidative stress and free radicals, further human trials are needed to fully elucidate the cellular
pathways activated by SQ in the regulation of cardiovascular ROS/RNS production.
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